	US 12,296,006 B2
	Anti-LY6H antibodies and antibody drug conjugates
Tinglei Gu, Andover, MA (US); Scott Michael Lonning, Westford, MA (US); Nels Eric Pederson, Mansfield, MA (US); Aleksandr Tkachev, Cambridge, MA (US); Klarisa Rikova, Reading, MA (US); and Sean A. Beausoleil, Essex, MA (US)
Assigned to Bluefin BioMedicine, Inc., Beverly, MA (US)
Filed by Bluefin BioMedicine, Inc., Beverly, MA (US)
Filed on Jul. 28, 2022, as Appl. No. 17/875,723.
Application 17/875,723 is a continuation of application No. 16/624,612, granted, now 11,434,303, previously published as PCT/US2018/040085, filed on Jun. 28, 2018.
Claims priority of provisional application 62/588,520, filed on Nov. 20, 2017.
Claims priority of provisional application 62/527,172, filed on Jun. 30, 2017.
Claims priority of provisional application 62/526,297, filed on Jun. 28, 2017.
Prior Publication US 2023/0192885 A1, Jun. 22, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C12N 15/13 (2006.01); A61K 33/244 (2019.01); A61K 39/00 (2006.01); C12N 15/00 (2006.01)

CPC A61K 39/39558 (2013.01) [A61K 33/243 (2019.01); A61K 47/68031 (2023.08); A61K 47/68035 (2023.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); A61K 33/244 (2019.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C12N 15/00 (2013.01)]

14 Claims

1. An anti-LY6H antibody, or antigen-binding portion thereof, comprising a heavy chain variable region comprising

a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 48, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 29, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 46, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 52, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 51, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 50; or

a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 55, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 29, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 28, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 57, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 51, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 50; or

a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 3, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 2, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 7, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 6; or

a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 63, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 62, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 61, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 7, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 6; or

a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 11, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 16, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 15, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 14.